A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection

Summary

This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S. commercial Dupixent® and CN commercial Dupixent® in healthy adult participants in China. A total of 294 healthy male adult participants, with 98 participants per treatment group across 3 groups.

Timeline

Start

2026-03-05

Primary completion

2026-09

Completion

2026-09

Drugs

Indications